| [1] |
Collins FS, Varmus H. A new initiative on precision medicine[J]. N Engl J Med, 2015, 372(9):793–795.
|
| [2] |
Ashley EA. The precision medicine initiative: a new national effort[J]. JAMA, 2015, 313(21):2119–2120.
|
| [3] |
Ong FS, Lin JC, Das K, et al. Translational utility of next-generation sequencing[J]. Genomics, 2013, 102(3):137–139.
|
| [4] |
Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: A guide for oncologists[J]. Crit Rev Oncol Hematol, 2015, 96(3):463–474.
|
| [5] |
Hinrichs JW, van Blokland WT, Moons MJ, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice[J]. Am J Clin Pathol, 2015, 143(4):573–578.
|
| [6] |
Xuan J, Yu Y, Qing T, et al. Next-generation sequencing in the clinic: promises and challenges[J]. Cancer Lett, 2013, 340(2):284–295.
|
| [7] |
Jessri M, Farah CS. Next generation sequencing and its application in deciphering head and neck cancer[J]. Oral Oncol, 2014, 50(4):247–253.
|
| [8] |
Tattini L, D’Aurizio R, Magi A. Detection of genomic structural variants from next-generation sequencing data[J]. Front Bioeng Biotechnol, 2015, 3:92.
|
| [9] |
Nakagawa H, Wardell CP, Furuta M, et al. Cancer whole-genome sequencing: present and future[J]. Oncogene, 2015.[Epub ahead of print]
|
| [10] |
Samorodnitsky E, Jewell BM, Hagopian R, et al. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing[J]. Hum Mutat, 2015, 36(9):903–914.
|
| [11] |
Lin X, Tang W, Ahmad S, et al. Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities[J]. Hear Res, 2012, 288(1–2):67–76.
|
| [12] |
Stranneheim H, Wedell A. Exome and genome sequencing: a revolution for the discovery and diagnosis of monogenic disorders[J]. J Intern Med, 2015.[Epub ahead of print]
|
| [13] |
Scheffler M, Schultheis A, Teixido C, et al. Ros1 rearrangements in lung adenocarcinoma: Prognostic impact, therapeutic options and genetic variability[J]. Oncotarget, 2015, 6(12):10577–10585.
|
| [14] |
Coco S, Truini A, Vanni I, et al. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine[J]. Curr Drug Targets, 2015, 16(1):47–59.
|
| [15] |
Nielsen MM, Tehler D, Vang S, et al. Identification of expressed and conserved human noncoding RNAs[J]. RNA, 2014, 20(2):236–251.
|
| [16] |
Yang KC, Yamada KA, Patel AY, et al. Deep rna sequencing reveals dynamic regulation of myocardial noncoding rnas in failing human heart and remodeling with mechanical circulatory support[J]. Circulation, 2014, 129(9):1009–1021.
|
| [17] |
Martens-Uzunova ES, Jalava SE, Dits NF, et al. Diagnostic and prognostic signatures from the small non-coding rna transcriptome in prostate cancer[J]. Oncogene, 2012, 31(8):978–991.
|
| [18] |
Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer[J]. Cancer, 2015, 121(4):631–639.
|
| [19] |
Shen T, Pajaro-Van de Stadt SH, Yeat NC, et al. Clinical applications of next generation sequencing in cancer: From panels, to exomes, to genomes[J]. Front Genet, 2015, 6:215.
|
| [20] |
Shih J, Bashir B, Gustafson KS, et al. Cancer Signature Investigation: ERBB2 (HER2)- Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary[J]. J Natl Compr Canc Netw, 2015, 13(8):947–952.
|
| [21] |
Gusnanto A, Tcherveniakov P, Shuweihdi F, et al. Stratifying tumour subtypes based on copy number alteration profiles using next-generation sequence data[J]. Bioinformatics, 2015, 31(16):2713–2720.
|
| [22] |
Fenizia F, De Luca A, Pasquale R, et al. Egfr mutations in lung cancer: From tissue testing to liquid biopsy[J]. Future Oncol, 2015, 11(11):1611–1623.
|
| [23] |
Yong E. Cancer biomarkers: Written in blood[J]. Nature, 2014, 511(7511):524–526.
|
| [24] |
Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types[J]. Mol Oncol, 2015, 9(4):783–790.
|
| [25] |
Frenel JS, Carreira S, Goodall J, et al. Serial next generation sequencing of circulating cell free DNA evaluating tumour clone response to molecularly targeted drug administration[J]. Clin Cancer Res, 2015. [Epub ahead of print]
|
| [26] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13):1199–1209.
|
| [27] |
O’Brien CP, Taylor SE, O’Leary JJ, et al. Molecular testing in oncology: Problems, pitfalls and progress[J]. Lung Cancer, 2014, 83(3):309–315.
|
| [28] |
Sima J, Gilbert DM. Complex correlations: replication timing and mutational landscapes during cancer and genome evolution[J]. Curr Opinion Genet Dev, 2014, 25:93–100.
|
| [29] |
Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes[J]. Science, 2013, 339(6127):1546–1558.
|
| [30] |
Lipson D, Capelletti M, Yelensky R, et al. Identification of new alk and ret gene fusions from colorectal and lung cancer biopsies[J]. Nat Med, 2012, 18(3):382–384.
|
| [31] |
Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(18):1689–1699.
|
| [32] |
Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer[J]. Translat Lung Cancer Res, 2014, 3(6):370–372.
|
| [33] |
Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches[J]. Clin Cancer Res, 2015, 21(16):3631–3639.
|
| [34] |
Azijli K, Stelloo E, Peters GJ, et al. New developments in the treatment of metastatic melanoma: Immune checkpoint inhibitors and targeted therapies[J]. Anticancer Res, 2014, 34(4):1493–1505.
|
| [35] |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252–264.
|
| [36] |
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124–128.
|
| [37] |
Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk[J]. BMC Cancer, 2015, 15:215.
|
| [38] |
Meng H, Cao Y, Qin J, et al. DNA methylation, its mediators and genome integrity[J]. Int J Biol Sci, 2015, 11(5):604–617.
|
| [39] |
Pilgrim SM, Pain SJ, Tischkowitz MD. Opportunities and challenges of next-generation DNA sequencing for breast units[J]. Br J Surg, 2014, 101(8):889–898.
|
| [40] |
Bennett NC, Farah CS. Next-generation sequencing in clinical oncology: next steps towards clinical validation[J]. Cancers (Basel), 2014, 6(4):2296–2312.
|